JP2023536437A5 - - Google Patents

Info

Publication number
JP2023536437A5
JP2023536437A5 JP2023504833A JP2023504833A JP2023536437A5 JP 2023536437 A5 JP2023536437 A5 JP 2023536437A5 JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023536437 A5 JP2023536437 A5 JP 2023536437A5
Authority
JP
Japan
Prior art keywords
disease
erap2
mhc
hla
inhibitor according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/043062 external-priority patent/WO2022026336A1/en
Publication of JP2023536437A publication Critical patent/JP2023536437A/ja
Publication of JP2023536437A5 publication Critical patent/JP2023536437A5/ja
Pending legal-status Critical Current

Links

JP2023504833A 2020-07-25 2021-07-23 小胞体アミノペプチダーゼ2(erap2)媒介性免疫応答の調節 Pending JP2023536437A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063056562P 2020-07-25 2020-07-25
US63/056,562 2020-07-25
US202163171672P 2021-04-07 2021-04-07
US63/171,672 2021-04-07
PCT/US2021/043062 WO2022026336A1 (en) 2020-07-25 2021-07-23 Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Publications (2)

Publication Number Publication Date
JP2023536437A JP2023536437A (ja) 2023-08-25
JP2023536437A5 true JP2023536437A5 (https=) 2024-07-30

Family

ID=77564145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504833A Pending JP2023536437A (ja) 2020-07-25 2021-07-23 小胞体アミノペプチダーゼ2(erap2)媒介性免疫応答の調節

Country Status (10)

Country Link
US (1) US20230059929A1 (https=)
EP (1) EP4188963A1 (https=)
JP (1) JP2023536437A (https=)
KR (1) KR20230043888A (https=)
CN (1) CN116194484A (https=)
AU (1) AU2021316196B2 (https=)
CA (1) CA3189755A1 (https=)
IL (1) IL299986A (https=)
MX (1) MX2023001059A (https=)
WO (1) WO2022026336A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4416286A1 (en) 2021-10-14 2024-08-21 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US12613286B2 (en) 2024-01-22 2026-04-28 Garrett Transportation I Inc. System and method for battery parameter recharacterization
CN118593462B (zh) * 2024-06-28 2026-01-27 沈阳药科大学 鼠尾草酸作为erap1的抑制剂在制备治疗强直性脊柱炎药物中的应用

Similar Documents

Publication Publication Date Title
Lyons et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
JP2023536437A5 (https=)
AU2016281772B2 (en) Detection of chromosome interactions
Merkel et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody–associated vasculitis
Stone et al. IgG4-related disease
EP3202914B2 (en) Method for treating a neurodegenerative disease
Puthia et al. IRF7 inhibition prevents destructive innate immunity—A target for nonantibiotic therapy of bacterial infections
El-Far et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
FI3774897T3 (fi) Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon
US12188081B2 (en) Bioinformatics methods of in silico validation and selection of circRNAs
Frade et al. Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy
EP3538891A2 (en) Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
Abe‐Hatano et al. Whole genome sequencing of 45 Japanese patients with intellectual disability
Lim et al. Exome sequencing identifies KIAA1377 and C5orf42 as susceptibility genes for monomelic amyotrophy
Turkunova et al. Molecular genetics and pathogenesis of the floating harbor syndrome: case report of long-term growth hormone treatment and a literature review
Friebus-Kardash et al. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis
Hsu et al. Effect of resistance training on satellite cells in old mice–a transcriptome study: Implications for sarcopenia
Schramm et al. Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates
JP2024515240A5 (https=)
EP3013976B1 (en) Method of predicting risk for type 1 diabetes before seroconversion
Gardet et al. Pristane-accelerated autoimmune disease in (SWR X NZB) F1 mice leads to prominent tubulointerstitial inflammation and human lupus nephritis-like fibrosis
Milazzo et al. UBE3A reinstatement restores behaviorand proteome in an Angelman syndrome mouse model of imprinting defects
Ismail Bioinformatics of Autoimmune Diseases
Zhang et al. Associations of 2,922 genetically predicted plasma protein levels with mental illness and response to treatment
Meijer et al. A primed immune transcriptional program is activated in oligodendroglia in multiple sclerosis